Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

What It Covers

BioCentury This Week examines biotech capital markets momentum amid geopolitical uncertainty, Xenon Pharmaceuticals' phase three epilepsy data validating the KV7 potassium channel target, and the shifting Friedreich's ataxia pipeline from mitochondrial stabilizers toward frataxin-restoring gene therapies, with at least five programs now in development.

Key Questions Answered

• •Biotech follow-on strength vs. venture lag: Over $7B was raised in follow-on financings in Q1 2026—nearly matching all of 2025—with deals like Xenon upsizing from $500M to $750M on strong data. However, venture financing sits at roughly $5.4B for the quarter, potentially the lowest since 2017, suggesting a lag between public and private market recovery cycles.
• •KV7 channel revival strategy: Xenon's azetukalner achieved a 42% reduction in median monthly seizure frequency versus placebo with an extraordinarily low p-value in phase three focal epilepsy. The molecule avoids predecessor GSK drug safety issues—skin discoloration and retinal abnormalities—by preventing dimerization via a novel chemical structure, with NDA submission planned for Q3 2025.
• •Dosing timing as a side effect mitigation tool: KV7 openers cause dizziness and somnolence by allowing potassium ions to flow out of neurons, stabilizing membrane potential. Xenon addresses this by extending the molecule's half-life for once-daily dosing administered in the evening, so peak side effects occur during sleep rather than waking hours—a replicable strategy for CNS drugs with sedating mechanisms.
• •Friedreich's ataxia gene therapy differentiation: Among five FA gene therapy programs, four use AAV vectors while Replay Holdings' spinout Calib uses herpes simplex virus vectors, which offer higher payload capacity. This allows delivery of the full frataxin gene with its native regulatory elements—exceeding AAV's five-kilobase limit—potentially producing more physiologically accurate protein expression across affected tissues.
• •FA accelerated approval pathway established: Alexio Therapeutics' LX2006 secured FDA agreement on an accelerated approval pathway targeting FA-associated cardiomyopathy, the leading cause of death in FA patients. The agreed endpoints are left ventricular mass index and frataxin expression levels—providing a regulatory template other FA gene therapy developers can reference when designing their own pivotal trial endpoints.